PPAR α activation by pemafibrate (a selective PPAR α modulator; SPPARM α) has been reported to be beneficial in enhancing metabolic dysregulation in patients with dyslipidemia (Ida, Kaneko & Murata, 2019). Here, PPARA is linked to metabolic syndrome.